Plasma NGAL level
PreclinicalBiologic
Plasma NGAL level is one of 36 biologic programs targeting Rhabdomyolysis. It is currently in Preclinical.
3
Indications
3
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
181 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Actos
TakedaPreclinical
Celexa
AbbViePreclinical
Voltaren
NovartisPreclinical
Cataflam
NovartisPreclinical
Plaquenil
Jazz PharmaceuticalsPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Velcade
SShilpa Grover, MD, MPH
Preclinical
Vancocin
HHikma Pharmaceuticals LLC
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Disalcid
JJoslin Diabetes Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Rhabdomyolysis1 trial
Plasma Neutrophil Gelatinase Associated Lipocalin Levels During Emergency Management of Rhabdomyolysis
Completed·—··NCT01544231·197 enrolled
Rheumatoid Arthritis1 trial
Evaluation of the Intestinal Microbiota and Bacterial Translocation in Patients With Rheumatoid Arthritis
Completed·—··NCT01961310·55 enrolled
Headache1 trial
S100B in the Care of Non-traumatic Headaches in the Emergency Department
Completed·—·N/A·NCT02683304·81 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Plasma NGAL level. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details